Document is current
Any future updates will be listed below
-
Authors
Krämer, Isabelle https://orcid.org/0000-0003-1667-4109
König, Laila
Luft, Thomas https://orcid.org/0000-0002-0387-1640
Hegenbart, Ute https://orcid.org/0000-0003-1917-6746
Schönland, Stefan https://orcid.org/0000-0002-4853-5579
Eichkorn, Tanja
Stadtherr, Peter
Selberg, Lorenz https://orcid.org/0000-0001-8331-4395
Müller-Tidow, Carsten
Dreger, Peter https://orcid.org/0000-0002-7429-8570
- License Information
-
More Information
Article History
Received: 5 November 2024
Revised: 5 January 2025
Accepted: 29 January 2025
First Online: 13 February 2025
Competing interests
: Isabelle Krämer reports training and travel grant from Janssen-Cilag, SOBi; honoraria from AbbVie, Lilly, Incyte, AstraZeneca (partly to institution); congress participation fee from Lilly, SOBi. Ute Hegenbart reports honorarium for talks: Janssen, Pfizer, Alnylam, Akcea, Prothena, Astra Zeneca; financial support of congress participation: Janssen, Prothena, Pfizer; advisory boards: Pfizer, Prothena, Janssen, Alexion; financial sponsoring of Amyloidosis Registry: Janssen. Peter Dreger reports consultancy for AbbVie, AstraZeneca, Beigene, BMS, Gilead, Miltenyi (all to institution); speakers bureau for AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Riemser, Roche (all to institution); research support from Riemser (all to institution); meeting attendance support from Beigene and Gilead; Participation on a Data Safety Monitoring Board for Novartis. The remaining authors declare no competing financial interests.
: The study was performed in accordance with the Declaration of Helsinki. All patients provided written informed consent to data collection and scientific evaluation before admission to alloHCT. Data analysis was approved by the institutional review board (Ethics Committee of the Medical Faculty of Heidelberg University, S-200/2010).
